TRATAMENTO DA PERTURBAÇÃO DISFÓRICA PRÉ-MENSTRUAL, UMA REVISÃO

Mariana Duarte Mangas

Resumo


Introdução: A Perturbação Disfórica Pré-Menstrual (PDPM) integra um conjunto de sintomas afectivos, comportamentais e somáticos que ocorrem mensalmente na fase lútea do ciclo menstrual. Afecta 3-8% das mulheres em idade fértil e constitui a condição mais severa e incapacitante da síndrome pré-menstrual, recentemente classificada como entidade nosológica categorizada nas Perturbações Depressivas do DSM-5.

Neste artigo efectua-se uma revisão bibliográfica sobre o tratamento da PDPM e é apresentado um caso clínico.

Métodos: Procedeu-se a uma pesquisa bibliográfica nas bases de dados PubMed e Scielo, utilizando os termos MeSH “premenstrual dysphoric disorder” e “treatment”.

Resultados/Conclusão: A PDPM apresenta características únicas relativamente às outras patologias depressivas no que diz respeito à sintomatologia e periodicidade. O tratamento farmacológico com inibidores selectivos da recaptação de serotonina constitui o tratamento de primeira linha, melhorando significativamente as queixas clínicas. A associação de quetiapina parece promissora quando existem respostas terapêuticas incompletas. O uso de suplemento de cálcio, a terapia cognitiva-comportamental e o vitex agnus-castus podem ser benéficos como estratégias coadjuvantes.
O tratamento da PDPM é provavelmente prejudicado pelo conhecimento incompleto da sua patogénese, pelo que mais estudos nessa área se impõem. A identificação de endofenótipos para a PDPM poderá permitir o desenvolvimento de tratamento personalizado e assim melhorar os resultados terapêuticos.


Palavras-chave


Perturbação Disfórica Pré-Menstrual; PDPM; síndrome pré-menstrual; tratamento; ISRSs.

Texto Completo:

PDF

Referências


Rapkin AJ, Lewis EI.: Treatment of premenstrual dysphoric disorder. Womens Health (Lond Engl). (2013 Nov); 9(6):537-56.

Epperson CN, Steiner M, Hartlage SA, Eriksoon E, Schmidt P, Jones I, Yonkers KA.: Premenstrual dysphoric disorder: evidence for a new category for DSM-5. Am J Psych (2012); 169:465–75.

Dennerstein L, Lehert P, Heinemann K.: Epidemiology of premenstrual symptoms and disorders. Menopause Int. (2012 Jun);18(2):48-51.

Valadares GC, Valadares Ferreira L., Correa Filho H, Romano-Silva MA.: Transtorno disfórico pré-menstrual revisão – conceito, história, epidemiologia e etiologia. Rev. Psiq. Clín. (2006); 33 (3); 117-123.

Zachar P, Kendler KS.: A diagnostic and statistical manual of mental disorders history of premenstrual dysphoric disorder. J Nerv Ment Dis. (2014 Apr); 202(4):346-52.

Cunningham J, Yonkers KA, O’Brien S, Eriksson E.: Update on research and treatment of premenstrual dysphoric disorder. Harv. Rev. Psychiatry (2009); 17(2), 120–137.

Wittchen HU, Becker E, Lieb R, Krause P.: Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med. (2002 Jan); 32(1):119-32.

Hong JP, Park S, Wang HR, Chang SM, Sohn JH, Jeon HJ, et al.: Prevalence, correlates, comorbidities, and suicidal tendencies of premenstrual dysphoric disorder in a nationwide sample of Korean women. Soc Psychiatry Psychiatr Epidemiol (2012); 47(12):1937–45.

Pilver CE, Libby DJ, Hoff RA.: Premenstrual dysphoric disorder as a correlate of suicidal ideation, plans, and at-tempts among a nationally representative sample. Soc Psy-chiatry Psychiatr Epidemiol (2013); 48(3):437–46.

Hantsoo L, Epperson CN.: Premenstrual Dysphoric Disor-der: Epidemiology and Treatment. Curr Psychiatry Rep. (2015 Nov); 17(11):87.

Steiner M, MacDougall M, Brown E.: The premenstrual symptoms screening tool (PSST) for clinicians. Arch. Womens Ment. Health (2003); 6(3), 203–209

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA: American Psychiatric Association; 2013.

Pearlstein T.: Treatment of Premenstrual Dysphoric Disor-der: Therapeutic Challenges. Expert Rev Clin Pharmacol (2016 Feb); 6:1-4.

Schüle C, Nothdurfter C, Rupprecht R.: The role of allo-pregnanolone in depression and anxiety. Prog Neurobiol (2014 Feb); 113:79-87.

Marjoribanks J Brown J, O'Brien PM, Wyatt K.: Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev (2013 Jun).

ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health (2013) 16:279–291.

Freeman EW, Rickels K, Yonkers KA, Kunz NR, McPher-son MK, Upton GV.: Venlafaxine in the treatment of premen-strual dysphoric disorder. Obstet. Gynecol (2001). 98(5 Pt 1), 737–744.

Pearlstein T. Psychotropic medications and other non-hormonal treatments for premenstrual disorders. Menopause Int (2012); 18(2), 60–64.

Jackson C. Jackson C, Pearson B, Girdler S, Johnson J, Hamer RM, Killenberg S, Meltzer-Brody S.: Double-blind, placebo-controlled pilot study of adjunctive quetiapine SR in the treatment of PMS/PMDD. Hum Psychopharmacol (2015 Nov); 30(6):425-34.

Herzog AG, Smithson SD, Fowler KM, Krishnamurthy KB, Sundstrom D, Kalayjian LA, Heck CN, Oviedo S, Correl-Leyva G, Garcia E, Gleason KA, Dworetzky BA.: Premenstrual dys-phoric disorder in women with epilepsy: relationships to poten-tial epileptic, antiepileptic drug, and reproductive endocrine factors. Epilepsy Behav (2011 Aug); 21(4):391-6.

Lopez LM, Kaptein AA, Helmerhorst FM.: Oral contracep-tives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev (2012);2:CD006586.

Smith RN, Studd JW, Zamblera D, Holland EF.: A ran-domized comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br. J. Obstet. Gynaecol (1995); 102(6), 475–484.

Mitwally MF, Kahn LS, Halbreich U.: Pharmacotherapy of premenstrual syndromes and premenstrual dysphoric disorder: current practices. Expert Opin Pharmacother (2002 Nov); 3(11):1577-90. Review.

Cronje WH1, Vashisht A, Studd JW.: Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod (2004 Sep);19(9):2152-5.

Frey B, Minuzzi L.: Comorbid bipolar disorder and pre-menstrual dysphoric disorder: real patients, unanswered ques-tions. Arch Womens Ment Health (2013); 16:79-81.

Vigod SN, Frey BN, Soares CN, Steiner M.: Approach to premenstrual dysphoria for the mental health practitioner. Psy-chiatr Clin North Am (2010 Jun); 33(2):257-72.

Frackiewicz EJ, Shiovitz TM.: Evaluation and management of premenstrual syndrome and premenstrual dysphoric disorder. J Am Pharm Assoc (2001); 41:437-47.

Daley A.: Exercise and premenstrual symptomatology: a comprehensive review. J. Womens Health (Larchmt.) (2009);18(6), 895–899.

Whelan AM, Jurgens TM, Naylor H.: Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a system-atic review. Can J Clin Pharmacol (2009); 16:407–29.

Lustyk MK, Gerrish WG, Shaver S, Keys SL.: Cognitive–behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch. Womens Ment. Health (2009); 12(2), 85–96.

Hunter MS, Ussher JM, Browne SJ, Cariss M, Jelley R, Katz M.: A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treat-ment for women with premenstrual dysphoric disorder. J. Psy-chosom. Obstet. Gynaecol (2002); 23(2), 193–199.

Bluth K, Gaylord S, Nguyen K, Bunevicius A, Girdler S.: Mindfulness-based Stress Reduction as a Promising Interven-tion for Amelioration of Premenstrual Dysphoric Disorder Symp-toms. Mindfulness (N Y). (2015 Dec); 6(6):1292-1302.

Jang SH, Kim DI, Choi MS.: Effects and treatment methods of acupuncture and herbal medicine for premenstrual syndrome/premenstrual dysphoric disorder: systematic review. BMC Complement Altern Med. (2014 Jan); 10;14:11.


Apontadores

  • Não há apontadores.